Walder Wyss advised Crédit Mutuel Equity, the international direct investment company of Crédit Mutuel Alliance Fédérale, in its Pacovis minority stake acquisition. As a result of a shareholder change
Tags :Walder Wyss
WalderWyss advised Klar on Bühlmann’s all shares acquisition. Vischer provided legal and tax advice to Dr. Roland P. Bühlmann and Marie-Thérèse Bühlmann in this transaction. Located in Schönenbuch (
Walder Wyss advised Helvetia on a successfully placed CHF 230 million senior bond with maturity in 2034 and a 1.95% coupon. The bond, guaranteed by Helvetia, will be used for general corporate purposes, including possible refinancings of outstanding
Walder Wyss advised Kanalservice Group, a portfolio company of Ufenau Capital Partners, on its acquisition of Roberit, Labosim Markierungs and Klose-Vital as part of the group’s ongoing growth strategy. Kanalservice Group is a full-service
On 23 May 2024, Houzy AG announced that Houzy and Devis.ch SA are merging. Walder Wyss advised Houzy Corporate/M&A with a team led by managing associates Dario Galli (pictured left) and Michael Kü
Walder Wyss advised SixPeaks Bio in securing USD 30 million in Series A financing led by founding investor Versant Ventures and a strategic collaboration with AstraZeneca. The latter, advised by Lenz & Staehelin, will provide additional,
Walder Wyss advised the funds managed by Perceptive Advisor, a privately owned hedge fund sponsor investing in biotechnology and life sciences sectors, on the secured term loan financing for up USD 50,000,000 granted to Sophia Genetics,
Walder Wyss, together with CastaldiPartners, advised Provost on its acquisition of Mino & Lorenzini. Walder Wyss’ team comprised corporate and M&A partner Luc Defferrard (pictured) and corporate / M&A associate Ken Savioz.
Lenz & Staehelin advised Vaudoise Assurances on all legal and tax aspects of the acquisition of 100% of the share capital of Prevanto. Walder Wyss advised the sellers on all legal aspects of the transaction. Active
Walder Wyss advised the funds managed by Pharmakon Advisors, an investor in non-dilutive debt for the life sciences industry and investment manager of the BioPharma credit funds. Banking and finance counsel Tervel Stoyanov (pictured left)
